StreetInsider.com News Articles

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Fri, 27 Feb 2026 04:00:00 -0500

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial

MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company’s initial entry into defense technology manufacturing. The Company also provided an update on its ongoing evaluation of majority-control acquisition opportunities in regulated national-security sectors.

Mr. Salvato previously served as Chief Executive

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Fri, 27 Feb 2026 04:00:00 -0500

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial

Mr. Salvato previously served as Chief Executive

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Fri, 27 Feb 2026 04:00:00 -0500

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial

Mr. Salvato previously served as Chief Executive

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Fri, 27 Feb 2026 04:00:00 -0500

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial

Mr. Salvato previously served as Chief Executive

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Fri, 27 Feb 2026 04:00:00 -0500

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial

Mr. Salvato previously served as Chief Executive

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Fri, 27 Feb 2026 04:00:00 -0500

Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial

Mr. Salvato previously served as Chief Executive

Form 424B5 Genenta Science S.p.A.

Tue, 27 Jan 2026 06:11:00 -0500

si-local-file:///var/storage/secattach/20260127/25895579.html

Form 424B5 Genenta Science S.p.A.

Tue, 27 Jan 2026 06:11:00 -0500

si-local-file:///var/storage/secattach/20260127/25895579.html

Form SCHEDULE 13G/A Genenta Science S.p.A. Filed by: Pierluigi Paracchi

Tue, 27 Jan 2026 06:09:00 -0500

si-local-file:///var/storage/secattach/20260127/25895551.html

Form SCHEDULE 13G/A Genenta Science S.p.A. Filed by: Pierluigi Paracchi

Tue, 27 Jan 2026 06:09:00 -0500

si-local-file:///var/storage/secattach/20260127/25895551.html

Form 6-K Genenta Science S.p.A. For: Jan 27

Tue, 27 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260127/25895535.html

Form 6-K Genenta Science S.p.A. For: Jan 27

Tue, 27 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260127/25895535.html

Form 6-K Genenta Science S.p.A. For: Jan 27

Tue, 27 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260127/25895536.html

Form 6-K Genenta Science S.p.A. For: Jan 27

Tue, 27 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260127/25895536.html

Form 6-K Genenta Science S.p.A. For: Jan 27

Tue, 27 Jan 2026 06:04:00 -0500

si-local-file:///var/storage/secattach/20260127/25895516.html

Form 6-K Genenta Science S.p.A. For: Jan 27

Tue, 27 Jan 2026 06:04:00 -0500

si-local-file:///var/storage/secattach/20260127/25895516.html

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Tue, 27 Jan 2026 03:00:00 -0500

Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies
ATC - a Defense-Sector Company: First Industrial Integration
Praexidia Foundation Joins as a Long-Term Strategic Shareholder
Corporate Name Change to Saentra Forge S.p.A.
Biotech Clinical Updates and Partnering Strategy
Cash, Cash Equivalents, and Marketable Securities of approx. $33 million

MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Tue, 27 Jan 2026 03:00:00 -0500

Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies
ATC - a Defense-Sector Company: First Industrial Integration
Praexidia Foundation Joins as a Long-Term Strategic Shareholder
Corporate Name Change to Saentra Forge S.p.A.
Biotech Clinical Updates and Partnering Strategy
Cash, Cash Equivalents, and Marketable Securities of approx. $33 million

MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Tue, 27 Jan 2026 03:00:00 -0500

Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies
ATC - a Defense-Sector Company: First Industrial Integration
Praexidia Foundation Joins as a Long-Term Strategic Shareholder
Corporate Name Change to Saentra Forge S.p.A.
Biotech Clinical Updates and Partnering Strategy
Cash, Cash Equivalents, and Marketable Securities of approx. $33 million

MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Tue, 27 Jan 2026 03:00:00 -0500

Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies
ATC - a Defense-Sector Company: First Industrial Integration
Praexidia Foundation Joins as a Long-Term Strategic Shareholder
Corporate Name Change to Saentra Forge S.p.A.
Biotech Clinical Updates and Partnering Strategy
Cash, Cash Equivalents, and Marketable Securities of approx. $33 million

MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and

Italy on the Move Brings 200+ Italy-US Biotech, Pharma and Investment Leaders Together in San Francisco During JPM Week

Mon, 19 Jan 2026 08:32:00 -0500

SAN FRANCISCO, Jan. 19, 2026 /PRNewswire/ -- More than 200 leaders from Italy and the United States—spanning biotech, pharma and investment—came together in San Francisco for the ninth edition of Italy on the Move, an Italy-hosted side event held during JPM Week to strengthen transatlantic dialogue on life sciences innovation and investment opportunities. The initiative was organized by the Italian Trade Agency, in collaboration with the Ministry of Foreign Affairs and International Cooperation, the Ministry of Enterprises and Made in

Italy on the Move Brings 200+ Italy-US Biotech, Pharma and Investment Leaders Together in San Francisco During JPM Week

Mon, 19 Jan 2026 08:32:00 -0500

SAN FRANCISCO, Jan. 19, 2026 /PRNewswire/ -- More than 200 leaders from Italy and the United States—spanning biotech, pharma and investment—came together in San Francisco for the ninth edition of Italy on the Move, an Italy-hosted side event held during JPM Week to strengthen transatlantic dialogue on life sciences innovation and investment opportunities. The initiative was organized by the Italian Trade Agency, in collaboration with the Ministry of Foreign Affairs and International Cooperation, the Ministry of Enterprises and Made in

Italy on the Move Brings 200+ Italy-US Biotech, Pharma and Investment Leaders Together in San Francisco During JPM Week

Mon, 19 Jan 2026 08:32:00 -0500

SAN FRANCISCO, Jan. 19, 2026 /PRNewswire/ -- More than 200 leaders from Italy and the United States—spanning biotech, pharma and investment—came together in San Francisco for the ninth edition of Italy on the Move, an Italy-hosted side event held during JPM Week to strengthen transatlantic dialogue on life sciences innovation and investment opportunities. The initiative was organized by the Italian Trade Agency, in collaboration with the Ministry of Foreign Affairs and International Cooperation, the Ministry of Enterprises and Made in

Italy on the Move Brings 200+ Italy-US Biotech, Pharma and Investment Leaders Together in San Francisco During JPM Week

Mon, 19 Jan 2026 08:32:00 -0500

SAN FRANCISCO, Jan. 19, 2026 /PRNewswire/ -- More than 200 leaders from Italy and the United States—spanning biotech, pharma and investment—came together in San Francisco for the ninth edition of Italy on the Move, an Italy-hosted side event held during JPM Week to strengthen transatlantic dialogue on life sciences innovation and investment opportunities. The initiative was organized by the Italian Trade Agency, in collaboration with the Ministry of Foreign Affairs and International Cooperation, the Ministry of Enterprises and Made in

Genenta Science CEO owns 10% stake through market purchases

Fri, 19 Dec 2025 05:13:04 -0500

Genenta Science (NASDAQ: GNTA) announced that Chief Executive Officer and Co-Founder Pierluigi Paracchi owns approximately 10% of the company's outstanding share capital as of December 19, 2025.
Paracchi holds 2,326,129 American Depositary Shares and ordinary shares in total, according to calculations made in accordance with Securities and Exchange Commission rules. The executive has acquired 30,000 ADSs through open-market purchases over time, with no reported sales of company securities.
All of Paracchi's transactions in Genenta securities have consisted of open-market purchases, as reported in the company's SEC filings. The Milan and New York-based company develops hematopoietic stem-cell-based immunotherapies for solid tumors.
Genenta is currently